Insmed Accounts Payable 2010-2025 | INSM

Insmed accounts payable for the quarter ending June 30, 2025 were $0.305B, a 4.87% increase year-over-year.

  • Insmed accounts payable for 2024 were $0.285B, a 32.66% increase from 2023.
  • Insmed accounts payable for 2023 were $0.215B, a 18.05% increase from 2022.
  • Insmed accounts payable for 2022 were $0.182B, a 45.66% increase from 2021.

Insmed Accounts Payable 2010-2025 | INSM

  • Insmed accounts payable for 2024 were $0.285B, a 32.66% increase from 2023.
  • Insmed accounts payable for 2023 were $0.215B, a 18.05% increase from 2022.
  • Insmed accounts payable for 2022 were $0.182B, a 45.66% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$248.3B
Amgen (AMGN)$155.9B
Gilead Sciences (GILD)$142.4B
Vertex Pharmaceuticals (VRTX)$99.3B
Bristol Myers Squibb (BMY)$96.1B
GSK (GSK)$81.1B
CSL (CSLLY)$67.7B
Regeneron Pharmaceuticals (REGN)$62.3B
Alnylam Pharmaceuticals (ALNY)$59.1B
Argenex SE (ARGX)$43.3B
BioNTech SE (BNTX)$25.2B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$20B
Incyte (INCY)$16.4B
Genmab (GNMSF)$16B
Genmab (GMAB)$15.7B
Illumina (ILMN)$15.2B
Ascendis Pharma (ASND)$12B
BioMarin Pharmaceutical (BMRN)$11B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.9B
Exelixis (EXEL)$10.3B
Moderna (MRNA)$9.6B
Verona Pharma American Depositary Share (VRNA)$9.1B
Bio-Techne Corp (TECH)$8.9B
Exact Sciences (EXAS)$8.7B
Halozyme Therapeutics (HALO)$8.5B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.1B
Guardant Health (GH)$7.9B